Literature DB >> 24084442

Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.

Greta Alì1, Nicla Borrelli, Giannini Riccardo, Agnese Proietti, Serena Pelliccioni, Cristina Niccoli, Laura Boldrini, Marco Lucchi, Alfredo Mussi, Gabriella Fontanini.   

Abstract

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm associated with asbestos exposure. Currently, the molecular mechanisms that induce MPM development are still unknown. The purpose of this study was to identify new molecular biomarkers for mesothelial carcinogenesis.
METHODS: We analyzed a panel of 84 genes involved in extracellular matrix remodeling and cell adhesion by polymerase chain reaction (PCR) array in 15 samples of epithelioid mesothelioma and 10 samples of reactive mesothelial hyperplasia (MH; 3 of 25 samples were inadequate for mRNA analysis). To validate the differentially expressed genes identified by PCR array, we analyzed 27 more samples by immunohistochemistry, in addition to the 25 samples already studied.
RESULTS: Twenty-five genes were differentially expressed in MPM and MH by PCR array. Of these we studied matrix metalloproteinase 7 (MMP7), MMP14, CD44, and integrin, alpha3 expression by immunohistochemistry in 26 epithelioid MPM and 26 MH samples from the entire series of 52 cases. We observed higher MMP14 and integrin, alpha3 expression in MPM samples compared with MH samples (p = 0.000002 and p = 0.000002, respectively). Conversely, CD44 expression was low in most (57.7%) mesothelioma samples but only in 11.5% of the MH samples (p = 0.0013). As regards MMP7, we did not observe differential expression between MH and MPM samples.
CONCLUSIONS: We have extensively studied genes involved in cell adhesion and extracellular matrix remodeling in MPM and MH samples, gaining new insight into the pathophysiology of mesothelioma. Moreover, our data suggest that these factors could be potential biomarkers for MPM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084442     DOI: 10.1097/JTO.0b013e3182a59f45

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

Review 1.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

2.  Biomarkers of cavernous angioma with symptomatic hemorrhage.

Authors:  Seán B Lyne; Romuald Girard; Janne Koskimäki; Hussein A Zeineddine; Dongdong Zhang; Ying Cao; Yan Li; Agnieszka Stadnik; Thomas Moore; Rhonda Lightle; Changbin Shi; Robert Shenkar; Julián Carrión-Penagos; Sean P Polster; Sharbel Romanos; Amy Akers; Miguel Lopez-Ramirez; Kevin J Whitehead; Mark L Kahn; Mark H Ginsberg; Douglas A Marchuk; Issam A Awad
Journal:  JCI Insight       Date:  2019-06-20

3.  Hyaluronan-positive plasma membrane protrusions exist on mesothelial cells in vivo.

Authors:  Ville Koistinen; Tiina Jokela; Sanna Oikari; Riikka Kärnä; Markku Tammi; Kirsi Rilla
Journal:  Histochem Cell Biol       Date:  2016-01-28       Impact factor: 4.304

4.  Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.

Authors:  Rossella Bruno; Greta Alì; Riccardo Giannini; Agnese Proietti; Marco Lucchi; Antonio Chella; Franca Melfi; Alfredo Mussi; Gabriella Fontanini
Journal:  Oncotarget       Date:  2017-01-10

Review 5.  CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Authors:  Lourdes Cortes-Dericks; Ralph Alexander Schmid
Journal:  Respir Res       Date:  2017-04-12

6.  The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.

Authors:  Viktoria Laszlo; Zsuzsanna Valko; Judit Ozsvar; Ildiko Kovacs; Tamas Garay; Mir Alireza Hoda; Thomas Klikovits; Paul Stockhammer; Clemens Aigner; Marion Gröger; Walter Klepetko; Walter Berger; Michael Grusch; Jozsef Tovari; Irene C Waizenegger; Balazs Dome; Balazs Hegedus
Journal:  J Mol Med (Berl)       Date:  2018-12-11       Impact factor: 4.599

7.  Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Authors:  Tania Villanova; Iacopo Gesmundo; Valentina Audrito; Nicoletta Vitale; Francesca Silvagno; Chiara Musuraca; Luisella Righi; Roberta Libener; Chiara Riganti; Paolo Bironzo; Silvia Deaglio; Mauro Papotti; Renzhi Cai; Wei Sha; Ezio Ghigo; Andrew V Schally; Riccarda Granata
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-18       Impact factor: 11.205

8.  A preliminary study: is fibulin 1 a friend or an enemy that needs to be silenced with siRNAs for mesothelioma?

Authors:  Asude Aksoy; Ahmet Tektemur; Elif Melek; Mustafa Kayfeci; Muhammed F Uslu; Ugurcan Cosar; Ebru Onalan
Journal:  Contemp Oncol (Pozn)       Date:  2021-01-04

9.  A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.

Authors:  Ming-Ming Shao; Xin Qiao; Qing-Yu Chen; Feng-Shuang Yi
Journal:  Thorac Cancer       Date:  2022-07-05       Impact factor: 3.223

10.  Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.

Authors:  Greta Alì; Rossella Bruno; Anello Marcello Poma; Ornella Affinito; Antonella Monticelli; Paolo Piaggi; Sara Ricciardi; Marco Lucchi; Franca Melfi; Antonio Chella; Sergio Cocozza; Gabriella Fontanini
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.